104
Participants
Start Date
August 16, 2011
Primary Completion Date
January 26, 2017
Study Completion Date
January 26, 2017
Pasireotide sub-cutaneous
Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
Mount Sinai School of Medicine, New York
Novartis Investigative Site, Berlin
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Berlin
Novartis Investigative Site, Córdoba
Allegheny Endocrinology Associates, Pittsburgh
Novartis Investigative Site, Granada
University of Pennsylvania Medical Center Univ Penn, Philadelphia
University of Maryland Medical Center, Baltimore
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Oldenburg
Emory University School of Medicine, Atlanta
Novartis Investigative Site, Ourense
Novartis Investigative Site, Marburg
Novartis Investigative Site, Pontevedra
Novartis Investigative Site, Göttingen
Mid South Endocrine Associates, Nashville
Vanderbilt University Medical Center, Nashville
Novartis Investigative Site, Valencia
Novartis Investigative Site, Valencia
Novartis Investigative Site, Aachen
Novartis Investigative Site, Mainz
Novartis Investigative Site, Frankfurt
Novartis Investigative Site, Frankfurt
John H Stroger Jr Hospital of Cook County, Chicago
Diabetes and Endocrinology Associates, PC, Omaha
University of Nebraska Medical Center, Omaha
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, München
St Josephs Hospital & Medical Center St Joes, Phoenix
Advanced Research, LLC, Peoria
Novartis Investigative Site, Augsburg
University of New Mexico Hospital UNM, Albuquerque
University of California at Los Angeles UCLA Tiverton, Los Angeles
Novartis Investigative Site, Songkhla
LA Biomedical Research at Harbor UCLA Medical Center, Torrance
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Würzburg
Oregon Health and Science University OHSU 5, Portland
Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle
Novartis Investigative Site, Moscow
Novartis Investigative Site, El Achrafiyé
Novartis Investigative Site, Cluj-Napoca
Novartis Investigative Site, Iași
Novartis Investigative Site, Joinville
Novartis Investigative Site, Fortaleza
Novartis Investigative Site, Londrina
Novartis Investigative Site, Rio de Janeiro
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, Prague
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Athens
Novartis Investigative Site, Thessaloniki
Novartis Investigative Site, Athens
Novartis Investigative Site, Thessaloniki
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Palma de Mallorca
Novartis Investigative Site, Badalona
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY